BridgeBio Pharma Inc. (NASDAQ:BBIO) on Wednesday announced a recent presentation of interim results from its Phase 3 FORTIFY trial for BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9.
Limb-girdle muscular dystrophy type R9 (LGMDR9, formerly 2I) is a rare genetic disease caused by mutations in the FKRP gene.
It causes progressive muscle weakness in the hips, shoulders, and legs, often leading to loss of mobility, breathing, and heart issues.
Early Data Is Encouraging
The interim analysis was presented at the MDA Clinical and Scientific Conference on Wednesday.
The data highlighted the consistent efficacy of BBP-418 across key clinical endpoints, with early improvements in ambulation observed as soon as three months after treatment initiation.
Based on these results, BridgeBio intends to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a potential U.S. launch anticipated in late 2026 or early 2027.
First Drug For Rare Genetic Disease
Additionally, the positive findings from the trial suggest that BBP-418 could become the first approved therapy for LGMD2I/R9, addressing a significant unmet medical need in this patient population.
The company is also exploring expedited approval pathways in Europe and plans to initiate clinical studies for younger patients with similar conditions.
In February, the company shared positive topline results from PROPEL 3 Phase 3 pivotal study of oral infigratinib in children with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short-limb dwarfism.
BridgeBio Pharma Technical Analysis
BridgeBio Pharma’s stock is currently trading 2.4% above its 20-day simple moving average (SMA) but is 3.1% below its 100-day SMA, indicating some short-term strength while struggling with longer-term trends.
Shares have increased 119.05% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 52.33, which is considered neutral territory, indicating a balanced market sentiment.
Meanwhile, MACD is at -1.2985, with the signal line at -1.9306, suggesting a bullish crossover as the MACD is above the signal line.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while the stock is not overbought or oversold, there is potential for upward movement.
- Key Resistance: $84.50
- Key Support: $69.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $82.96. Recent analyst moves include:
- JP Morgan: Overweight (Raises Target to $94.00) (Mar. 10)
- William Blair: Initiated with Outperform (Mar. 10)
- Truist Securities: Buy (Raises Target to $95.00) (Feb. 25)
Top ETF Exposure
- Vanguard Russell 2000 ETF (NASDAQ:VTWO): 0.41% Weight
- iShares Russell 2000 Growth ETF (NYSE:IWO): 0.77% Weight
- SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI): 2.49% Weight
BBIO Price Action: BridgeBio Pharma shares were down 0.52% at $71.02 during premarket trading on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments